Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma

Razi, Murtuza; Gu, Jianping; He, Xu; Ahmed, Mohammed Jameeluddin

doi:10.1016/j.jimed.2020.10.006

Cited by 8 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, by comparing cTACE to DEB-TACE, the majority of studies and meta-analyses have found slightly greater variations in liver function profiles and the prevalence of PES with cTACE. 15 This finding is consistent with pharmacokinetic profiles studied in preclinical research. 8 , 9 …”

Section: Discussionsupporting

confidence: 86%

Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma

Razi

Safiullah²,

et al. 2022

Journal of Interventional Medicine

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma

Razi

Safiullah²,

et al. 2022

Journal of Interventional Medicine

Self Cite

View full text Add to dashboard Cite

“…Currently, the pleasing survival profile has been noticed in several studies. 19 , 20 , 28 For instance, a meta-analysis study suggests that DEB-TACE exhibits improved PFS and OS over cTACE in treating HCC patients. 28 In line with previous studies, the present study revealed that DEB-TACE realized prolonged PFS (median (95% CI): 10.0 (9.0–11.0) months vs. 6.0 (4.3–7.7) months, P < .001) and OS (median (95% CI): 21.0 (18.6–23.4) months vs. 16.0 (13.8–18.2) months, P = .003) compared to cTACE.…”

Section: Discussionmentioning

confidence: 99%

“… 18 (2) DEB-TACE realized sustained release of the drug within a period of time, which provided more stable efficacy compared with cTACE. 19 (3) DEB-TACE had better embolization effects because of its individualized size options. (4) DEB-TACE reduced the occurrence of severe hepatic fibrosis, while the latter factors induced HCC progression.…”

Section: Discussionmentioning

confidence: 99%

The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma

Liang

Kuang

et al. 2023

Cancer Biology & Therapy

View full text Add to dashboard Cite

Objective Limited studies have reported the impact of drug-eluting bead transarterial chemoembolization (DEB-TACE) on hepatic fibrosis in hepatocellular carcinoma (HCC). This study evaluated multiple hepatic fibrosis indicators, aiming to comprehensively compare the influence of DEB-TACE and conventional transarterial chemoembolization (cTACE) on hepatic fibrosis in treating HCC patients. Methods Intermediate/advanced HCC patients (N = 121) were divided into the DEB-TACE group (n = 62) and the cTACE group (n = 59) based on their chosen treatment. Serum hyaluronic acid (HA), pro-collagen type-III (PC-III), collagen type-IV (IV-C), and laminin (LN) were detected; aminotransferase to platelet ratio index (APRI) and fibrosis index based on the four factors (FIB-4) were calculated; liver stiffness measurement (LSM) was assessed by real-time shear wave elastography. Results HA, PC-III, IV-C, and LN at 1 month after the second TACE and at 12 months after the first TACE were all decreased in DEB-TACE group compared with cTACE group (all P < .050). Then, APRI, FIB-4, and LSM were further assessed, which also showed a decreasing trend at aforementioned timepoints in DEB-TACE group compared with cTACE group (all P < .050). Additionally, the multivariate logistic regression analysis revealed that DEB-TACE (vs. cTACE) was independently associated with reduced occurrence of severe hepatic fibrosis at 12 months (OR = 0.215, 95%CI: 0.058–0.802, P = .022). Concerning the liver function indexes, alanine aminotransferase, aspartate aminotransferase, and total bilirubin after treatment were not different between the two groups (all P > .050). Conclusion DEB-TACE displays attenuated hepatic fibrosis progression and noninferior tolerance compared to cTACE in treating intermediate- or advanced-stage HCC patients.

show abstract

“…Factors including types of embolic materials, drug carriers, and drug-load volume of carriers significantly influence the outcome of embolization. 14 , 15 Recently, various multi-functional embolic materials have been developed and applied clinically to replace the simple filling materials, providing more options for endovascular embolization. 16 Standardized strategies for selecting optimum embolic materials and their precise use for specific diseases are topics of PIR.…”

Section: Precise Selection and Application Of Drugs Materials And Dev...mentioning

confidence: 99%

Precision interventional radiology

Fang

Chen

et al. 2021

Journal of Interventional Medicine

View full text Add to dashboard Cite

Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma

Cited by 8 publications

References 30 publications

Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma

Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma

The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma

Precision interventional radiology

Contact Info

Product

Resources

About